The good, the bad, and the ugly: Should we completely banish human albumin from our intensive care units?

Anesthesia and Analgesia

Volumn 91, Issue 4, 2000, Pages 887-895

  Boldt, Joachim ^a  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN;

ARTICLE; CAPILLARY LEAK SYNDROME; EVIDENCE BASED MEDICINE; FLUID BALANCE; FLUID THERAPY; HEMODYNAMICS; HYPOVOLEMIA; INTENSIVE CARE UNIT; MICROCIRCULATION; PATIENT CARE; PRIORITY JOURNAL;

EID: 0033804695     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-200010000-00022     Document Type: Article

References (93)

1. The rational administration of colloids
2. The rationale for fluid restriction during treatment for ARDS
3. A multicenter randomized, controlled clinical trial of transfusion requirements in critical care
4. Effects of red cell transfusion on oxygen consumption following fluid resuscitation in septic shock
5. Blood transfusion increases the risk of infection after trauma
6. Human albumin administration in critically ill patients: Systematic review of randomised controlled trials
7. Fluid resuscitation with colloids or crystalloids in critically ill patients: A systematic review of randomised trials
8. Volume replacement strategies on intensive care units: Results from a postal survey
9. Survey of colloid usage in British intensive care units
10. Albumin and non-protein colloid solution use in US academic health centers
11. Albumin utilization in a university hospital
12. Human albumin administration in critically ill patients
13. Current prospects for the treatment of clinical sepsis
14. Leukocyte adhesion to vascular endothelium
15. Capillary permeability in septic patients
16. Increased systemic microvascular albumin flux in septic shock
17. Changes in plasma levels of thrombomodulin during haemodialysis
18. Immune consequences of hypovolemic shock and resuscitation
19. Sepsis and inflammation: The process of dying from critical illness
20. Objectives for the treatment of the microcirculation in ischemia, shock, and reperfusion
21. Safety of human albumin as a constituent of biologic therapeutic products
22. Therapeutic use of albumin
23. Colloid oncotic pressure: Clinical significance
24. Reduction in colloid osmotic pressure associated with fatal progression of cardiopulmonary failure
25. Pulmonary edema associated with reduction in plasma oncotic pressure
26. Capillary leak syndrome with pulmonary edema
27. Postoperative albumin infusion therapy based on colloid osmotic pressure: A prospective randomized trial
28. Does reduced colloid oncotic pressure increase pulmonary dysfunction in sepsis
29. The effect of sepsis and reduced colloid osmotic pressure on pulmonary edema
30. Serum albumin: Touchstone or totem?
31. Unique feature of albumin: A brief review
32. Albumin and Ricinus communis agglutinin decrease endothelial permeability via interactions with matrix
33. Human neutrophil activation and increased adhesion by various resuscitation fluids
34. Certain batches of albumin solutions influence the expression of endothelial cell adhesion molecules
35. Incidence and severity of anaphylactoid reactions to colloid volume substitution
36. Inadvertent metal loading of critically ill patients with acute renal failure by human albumin solution infusion therapy
37. Hypotension associated with prekallikrein activator (Hageman factor fragments) in plasma protein fraction
38. Comparison of albumin and hespan on myocardial contractility
39. Heparin-like activity of albumin
40. On the inhibitory effects of albumin on platelet aggregation
41. Differential effects of serial hemodilution with hydroxyethyl starch, albumin, and 0.9% saline on whole blood coagulation
42. Primary hemostasis in hemodilution: Infusion solutions
43. Circulating ICAM-1 isoforms: Diagnostic prospects for inflammatory and immune disorders
44. Practice parameters for hemodynamic support of sepsis in adult patients in sepsis
45. Capillary leak, oedema and organ failure: Breaking the triad
46. Plugging the leaks? New insights into synthetic colloids
47. Pulmonary effects of albumin resuscitation for severe hypovolemic shock
48. Pentafraction reduces the lung lymph response after endotoxin administration in the ovine model
49. Limiting edema in neonatal cardiopulmonary bypass with narrow range molecular weight hydroxyethyl starch
50. Use of intravenous albumin in the critically ill patient
51. Increased vascular permeability: Major cause of hypoalbuminaemia in disease and injury
52. Albumin synthesis
53. Effect of endotoxin on capillary permeability to macromolecules
54. Implications of malnutrition in the surgical patient
55. Review of the rapid normalization of serum albumin with modified total parenteral nutrition solutions
56. The treatment of hypoalbuminemia in the critically ill patient
57. Efficacy of albumin supplementation in the surgical intensive care unit: A prospective, randomized study
58. Randomized, double-blind study of intervenous human albumin in hypoalbuminemic patients receiving total parenteral nutrition
59. Albumin supplementation in the critically ill
60. Effect of hypoalbuminemia and parenteral nutrition on free water excretion and electrolyte-free water resorption
61. Analbuminemia: A natural model of metabolic compensatory systems
62. Hemodynamic and oxygen transport effects of pentastarch in burn resuscitation
63. Major burns managed without blood or blood products
64. Effects of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis
65. Albumin improves the response to diuretics in patients with cirrhosis and ascites: Results of a randomized, controlled trial
66. Randomized comparative study of hemaccel vs. albumin infusion after total paracentesis in cirrhotic patients with refractory ascites
67. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracenesis
68. Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis
69. Utilisation des solutions d'albumine humaine en anesthesie-reanimation chirurgicale de l'adulte
70. Human albumin solutions: Consensus statements for use in selected clinical situations
71. The use of albumin in clinical practice
72. A paradigm for consensus: The university hospital consortium guidelines for the use of albumin, nonprotein colloids, and crystalloid solutions
73. Crystalloids versus colloids in fluid resuscitation: A systematic review
74. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
75. Effects of hetastarch and albumin on coagulation in patients with septic shock
76. Effects of pentastarch and albumin infusion on cardiorespiratory function and coagulation in patients with severe sepsis and systemic hypoperfusion
77. Colloid solutions in the critically ill: A randomised comparison of albumin and polygeline. 1. Outcome and duration of stay in the intensive care unit
78. Colloid solutions in the critically ill: A randomised comparison of albumin and polygeline. 2. Serum albumin concentration and incidences of pulmonary edema and acute renal failure
79. Influence of different volume therapies and pentoxifylline infusion on circulating soluble adhesion molecules in critically ill patients
80. The effects of albumin versus hydroxyethyl starch solution on cardiorespiratory and circulatory variables in critically ill patients
81. Influence of different volume therapy regimens on regulators of circulation in the critically ill
82. Influence of different volume therapies on platelet function in the critically ill
83. Influence of volume therapy and pentoxifylline infusion on circulating adhesion molecules in trauma patients
84. Volume therapy in the critically ill: Is there a difference?
85. Distribution of normal saline and 5% albumin infusions in septic patients
86. Wonderful albumin?
87. Human albumin administration in critically ill patients: I would not want an albumin transfusion
88. Crystalloid-colloid controversy revisited
89. Albumin industry launched global promotion
90. National estimates of intensive care utilization on costs: Canada and the United States
91. Albumin abuse in intensive care medicine
92. Costs of alternative colloid solutions
93. Crystalloid and colloid fluid therapy in resuscitation and subsequent ICU management